CD86 and neoplasm: Treatment with MCP led to an increase in CD86 expression and TNF-α secretion, indicative of enhanced M1 polarization, while reducing CD206 and CD163 expression along with IL-10 secretion (Figure 8B–F), thus supporting a shift towards a more anti-tumor immune response.